Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
PhaseBio Pharmaceuticals, Inc is a biotechnology business based in the US. PhaseBio Pharmaceuticals shares (PHAS) are listed on the NASDAQ and all prices are listed in US Dollars. PhaseBio Pharmaceuticals employs 50 staff and has a trailing 12-month revenue of around USD$1.1 million.
|Latest market close||USD$3.36|
|52-week range||USD$2.6 - USD$6.7|
|50-day moving average||USD$3.8262|
|200-day moving average||USD$3.9159|
|Wall St. target price||USD$14.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.623|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-17.04%|
|1 month (2020-12-15)||-24.32%|
|3 months (2020-10-15)||-1.18%|
|6 months (2020-07-15)||-31.01%|
|1 year (2020-01-15)||-36.36%|
|2 years (2019-01-15)||-8.45%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Revenue TTM||USD$1.1 million|
|Gross profit TTM||USD$-28,550,000|
|Return on assets TTM||-60.73%|
|Return on equity TTM||-211.62%|
|Market capitalisation||USD$95.7 million|
TTM: trailing 12 months
There are currently 2.6 million PhaseBio Pharmaceuticals shares held short by investors – that's known as PhaseBio Pharmaceuticals's "short interest". This figure is 29% down from 3.7 million last month.
There are a few different ways that this level of interest in shorting PhaseBio Pharmaceuticals shares can be evaluated.
PhaseBio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of PhaseBio Pharmaceuticals shares currently shorted divided by the average quantity of PhaseBio Pharmaceuticals shares traded daily (recently around 185873.19660537). PhaseBio Pharmaceuticals's SIR currently stands at 14.14. In other words for every 100,000 PhaseBio Pharmaceuticals shares traded daily on the market, roughly 14140 shares are currently held short.
However PhaseBio Pharmaceuticals's short interest can also be evaluated against the total number of PhaseBio Pharmaceuticals shares, or, against the total number of tradable PhaseBio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PhaseBio Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 PhaseBio Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.2651% of the tradable shares (for every 100,000 tradable PhaseBio Pharmaceuticals shares, roughly 265 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against PhaseBio Pharmaceuticals.
Find out more about how you can short PhaseBio Pharmaceuticals stock.
We're not expecting PhaseBio Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, PhaseBio Pharmaceuticals's shares have ranged in value from as little as $2.6 up to $6.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PhaseBio Pharmaceuticals's is 1.9107. This would suggest that PhaseBio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.